MTOR and ovarian carcinoma: In addition, the anti-proliferative and anti-angiogenic effects of thioridazine on ovarian carcinoma cells might be caused by inhibition of the PI3K/Akt and FAK/ mammalian target of rapamycin (mTOR) pathways in vitro [6, 7].